Norton A J, Isaacson P G
Department of Histopathology, University College & Middlesex School of Medicine, London, UK.
Histopathology. 1989 May;14(5):437-46. doi: 10.1111/j.1365-2559.1989.tb02180.x.
Recently, monoclonal antibodies capable of phenotyping malignant lymphomas in routinely fixed and processed tissue have become available. Some of these reagents identify lineage-restricted variants of the leucocyte common molecule, whereas others identify unique fixation-resistant epitopes on lymphoid cells, some of which are shared by non-lymphoid tissues. A new generation of antibodies recognizing 'classical' leucocyte antigens such as CD3 are also emerging. Refinements in antigen detection systems, especially for immunoglobulin recognition, combined with these new reagents promise to improve the accuracy of lymphoma diagnosis in routine histopathology. These new antibodies are reviewed, and their limitations, cross reactivities and profiles of staining in lymphoreticular disease are discussed. A strategy for their optimal use is proposed.
最近,能够对常规固定和处理的组织中的恶性淋巴瘤进行表型分析的单克隆抗体已经问世。其中一些试剂可识别白细胞共同分子的谱系限制性变体,而其他试剂则可识别淋巴样细胞上独特的抗固定表位,其中一些表位为非淋巴样组织所共有。新一代识别“经典”白细胞抗原(如CD3)的抗体也正在出现。抗原检测系统的改进,特别是针对免疫球蛋白识别的改进,与这些新试剂相结合,有望提高常规组织病理学中淋巴瘤诊断的准确性。本文对这些新抗体进行了综述,并讨论了它们的局限性、交叉反应性以及在淋巴网状疾病中的染色情况。还提出了它们的最佳使用策略。